Ovarian cancer

GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Retrieved on: 
Monday, March 25, 2024
Ovarian cancer, Health, Comprehensive, Cardiovascular disease, Gene, Genetic testing, DSM-IV codes, Risk, Patient, HBOC, Breast, Risk assessment, Publication, Cancer, Breast cancer, Physician, Vaccine

Oncology, Cardiovascular, and Metabolic Disease Coverage: GeneType's Comprehensive Risk Assessment Test covers a diverse range of diseases, providing physicians and patients with a complete understanding of an individual's risk profile.

Key Points: 
  • Oncology, Cardiovascular, and Metabolic Disease Coverage: GeneType's Comprehensive Risk Assessment Test covers a diverse range of diseases, providing physicians and patients with a complete understanding of an individual's risk profile.
  • With an increasing emphasis on personalized medicine and preventative healthcare, the demand for comprehensive genetic risk assessments is expected to grow significantly.
  • GENE’s CEO Simon Morriss, commented “As pioneers in risk assessment testing, we are thrilled to introduce our latest GeneType Comprehensive Risk Assessment Test.
  • The Comprehensive Risk Assessment Test marks a significant step towards realizing this vision, offering a transformative tool for healthcare providers and their patients.

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Retrieved on: 
Monday, March 25, 2024
Ovarian cancer, Gene, Clinical Cancer Research, Erasmus MC, Data analysis, Colorectal cancer, Progression-free survival, Patient, Neoplasm, Triple-negative breast cancer, Tumor microenvironment, Manuscript, Pancreatic cancer, Cancer, Doctor of Philosophy, MD, Epithelium, PD-L1, AIM, Liver, RNA, Vaccine

The manuscript titled “ Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses ,” appears in the journal Clinical Cancer Research, one of oncology’s most prestigious journals.

Key Points: 
  • The manuscript titled “ Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses ,” appears in the journal Clinical Cancer Research, one of oncology’s most prestigious journals.
  • Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and tumors.
  • Post-Ampligen, the increased peripheral abundance of BTLA+XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes.
  • Additionally, the changes in the tumor microenvironment we see in pancreatic cancer are similar to those we have seen in triple-negative breast cancer, ovarian cancer and colorectal cancer metastatic to the liver.

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, Ovarian cancer, Conference, Survival, AML, Carcinoma, RECIST, Patient, SAN, Multiple myeloma, KRON, Cancer, IRF4, Lung cancer, IND, AACR, Investment, KAT, CDK9, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth-quarter and full-year 2023 financial results.

Key Points: 
  • “In 2023, we made great progress across our portfolio and business.
  • Kronos Bio extended its expected cash runway by a year, into the second half of 2026, through restructurings and resource optimization.
  • Net Loss: Net loss for the fourth quarter of 2023 was $25.3 million, or $0.43 per share, including non-cash stock-based compensation expense of $5.2 million.
  • Net loss for the full-year 2023 was $112.7 million, or $1.95 per share, including non-cash stock-based compensation expense of $25.0 million.

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Retrieved on: 
Thursday, March 21, 2024
Research, Common stock, Ovarian cancer, IHC, Head, Therapeutic index, NSCLC, Immunotherapy, HNSCC, Patient, Neoplasm, Cohort, Tumor microenvironment, Observation, DESC, PDAC, Lung cancer, DLT, Investment, Clinical trial, Cancer, PIPE, ATM, Safety, Pharmacokinetics, Therapy, ADC, FACT, Pharmaceutical industry

BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2023, and provided a corporate update.

Key Points: 
  • BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2023, and provided a corporate update.
  • Approximately 54% of subjects have experienced grade 2, and 6% of subjects have experienced grade 3 treatment emergent adverse events (TEAEs).
  • As of December 31, 2023, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments of $120.8 million.
  • As of March 20, 2024, the outstanding number of shares of Common Stock of Pyxis Oncology was 58,133,375.

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Ovarian cancer, Head, Uterine cancer, GSK, Patient, Dendreon, Commercial, Cancer, Bristol Myers Squibb, Neoplasm, Melanoma, TCR, Therapy, Research, MAGEA4, Sarcoma, GMP, Safety, Pharmacokinetics, Amgen, QC, CDMO, Development, Prevalence, Half-life, RECIST, Senior, FDA, Lung cancer, Administration, Conference, Entrepreneurship, Bank, Corr, Messenger, Protein, Pharmacology, Uveal melanoma, Pharmaceutical industry

“Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.

Key Points: 
  • “Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.
  • For IMA203CD8 GEN2, Immatics cleared dose level 4a (DL4a, up to ~1.6x109 TCR-T cells) in December 2023, which is currently intended to be the target dose for further development.
  • A next data update for both Phase 1b cohorts with IMA203 GEN1 and IMA203CD8 GEN2 is planned for 2H 2024.
  • On September 11, 2023, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Retrieved on: 
Wednesday, March 20, 2024
Ovarian cancer, AIM, Education minister

OCALA, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website.

Key Points: 
  • OCALA, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website.
  • For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, provides an overview of Advanced Recurrent Ovarian Cancer and its unmet need, as well as the Company’s associated milestones with its clinical development program.

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on: 
Tuesday, March 19, 2024
Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points: 
  • HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
  • The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
  • Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
  • “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.

Carina Biotech to Present Three Poster Presentations at AACR Annual Meeting 2024

Retrieved on: 
Monday, March 18, 2024
Ovarian cancer, Brain, Immunotherapy, Colorectal cancer, Patient, Lead, Research, Doctor of Philosophy, University of Adelaide, University, GMP, AACR, Biomedical sciences, Stomach, Liver, Pharmaceutical industry

ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from studies of its LGR5-targeting CAR-T program in colorectal cancer and ovarian cancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.

Key Points: 
  • ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from studies of its LGR5-targeting CAR-T program in colorectal cancer and ovarian cancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.
  • “We are looking forward to sharing data related to our LRG-5 targeted CAR-T program in three poster presentations at the upcoming AACR annual meeting.
  • One of the posters will highlight the GMP manufacturing and testing findings for our lead LGR5-targeted CAR-T cell therapy candidate CNA3103, that is currently being evaluated in a Phase 1/2 clinical trial for the treatment of adult patients with metastatic colorectal cancer,” stated Deborah Rathjen, PhD, Carina’s Chief Executive Officer.
  • “Our research team will also be presenting preclinical data that demonstrate the potential to develop our LGR5-targeting CAR-T cells as a novel immunotherapy for ovarian cancer and that expand the preclinical body of evidence across a diverse range of cancer families, including ovarian, brain, liver, and stomach, where LGR5-targeting CAR-T cells may be harnessed.”
    Lead Author: Jade Foeng, PhD, Chemokine Biology Laboratory, Department of Molecular and Biomedical Science, The University of Adelaide, South Australia

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer

Retrieved on: 
Monday, March 18, 2024
Ovarian cancer, Mutation, Serum, Patient, Pharming, SGO, Gynecologic Oncology (journal), Platinum, Pharmaceutical industry

Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets the TP53 Y220C mutation in solid tumors.

Key Points: 
  • Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets the TP53 Y220C mutation in solid tumors.
  • These data were featured today in a late-breaking oral presentation at the 2024 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer being held March 16-18, 2024 in San Diego, CA.
  • “In this Phase 1 study, we observed promising efficacy of rezatapopt in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation.
  • Our registrational, tumor-agnostic PYNNACLE Phase 2 trial, which includes an ovarian cancer cohort, remains on track to initiate in the first quarter of this year.

Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President

Retrieved on: 
Monday, March 18, 2024
Georgetown University Law Center, Ovarian cancer, Development, Acceleration, California State University, Luminex Corporation, Information technology, Standard of care, Senior, Respiratory disease, University, Gynaecology, Woman, Doctor of Philosophy, Research and development, Endometriosis, Drug development, Dana–Farber Cancer Institute, Therapy, Amgen, DIA, Human resources, Medical device

AUSTIN, Texas, March 18, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President effective April 1, 2024. Dr. Milligan will report to Nicole Sandford, who will remain CEO. The Company has also promoted Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team reporting directly to Dr. Milligan, following the departure of Dr. Jody Berry.

Key Points: 
  • The Company has also promoted Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team reporting directly to Dr. Milligan, following the departure of Dr. Jody Berry.
  • She has demonstrated success in supporting pipeline and product development in both oncology and non-oncology disease areas, with recent emphasis in women’s health.
  • Dr. Milligan is a known and respected leader in women’s health who drives cross-functional strategies to achieve corporate success.
  • As President, Dr. Milligan will be a key member of the executive leadership team with direct responsibility for the Research and Development, Operations, Information Technology, and Human Resources functions.